<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: <z:hpo ids='HP_0002902'>Hyponatremia</z:hpo> caused by excessive <z:mp ids='MP_0006316'>natriuresis</z:mp> is common in patients with aneurysmal <z:hpo ids='HP_0002138'>subarachnoid hemorrhage</z:hpo> (SAH) </plain></SENT>
<SENT sid="1" pm="."><plain><z:mp ids='MP_0006316'>Natriuresis</z:mp> decreases the total blood volume through osmotic <z:mp ids='MP_0001762'>diuresis</z:mp> and increases the risk of symptomatic <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>In such patients, hypervolemic therapy is difficult to achieve without causing <z:hpo ids='HP_0002902'>hyponatremia</z:hpo> because <z:chebi fb="199" ids="26708">sodium</z:chebi> replacement provokes further <z:mp ids='MP_0006316'>natriuresis</z:mp> and osmotic <z:mp ids='MP_0001762'>diuresis</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>We examined the effects of <z:chebi fb="2" ids="17650">hydrocortisone</z:chebi>, which promotes <z:chebi fb="199" ids="26708">sodium</z:chebi> retention, in patients with SAH </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: Twenty-eight SAH patients were randomized into 2 groups after direct surgery: group 1 patients without <z:chebi fb="2" ids="17650">hydrocortisone</z:chebi> treatment (n=14) and group 2 patients with <z:chebi fb="2" ids="17650">hydrocortisone</z:chebi> treatment (1200 mg/d for 10 days; n=14) </plain></SENT>
<SENT sid="5" pm="."><plain>Both groups underwent hypervolemic therapy by aggressive <z:chebi fb="199" ids="26708">sodium</z:chebi> and water replacement </plain></SENT>
<SENT sid="6" pm="."><plain>The goal of the hypervolemic therapy was to maintain the serum <z:chebi fb="199" ids="26708">sodium</z:chebi> level &gt;140 mEq/L and the central venous pressure (CVP) within 8 to 12 cm <z:chebi fb="2" ids="29375,33813">H2O</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: Group 2 demonstrated a lower <z:chebi fb="199" ids="26708">sodium</z:chebi> excretion (P&lt;0.05) and higher serum <z:chebi fb="199" ids="26708">sodium</z:chebi> level (P&lt;0.05) compared with group 1 </plain></SENT>
<SENT sid="8" pm="."><plain><z:hpo ids='HP_0002902'>Hyponatremia</z:hpo> developed in 6 patients (43%) in group 1 and 0 patients in group 2 (P&lt;0.05) </plain></SENT>
<SENT sid="9" pm="."><plain>Group 2 also demonstrated a lower urine volume, lower infusion volume (P&lt;0.05) required for hypervolemic therapy, and higher CVP (P&lt;0.05) </plain></SENT>
<SENT sid="10" pm="."><plain>Failure to maintain CVP was observed in 12 patients (86%) in group 1 and 3 patients (21%) in group 2 (P&lt;0.05) </plain></SENT>
<SENT sid="11" pm="."><plain><z:chebi fb="2" ids="17650">Hydrocortisone</z:chebi> caused no serious side effects </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSIONS: <z:chebi fb="2" ids="17650">Hydrocortisone</z:chebi> clearly attenuates excessive <z:mp ids='MP_0006316'>natriuresis</z:mp> </plain></SENT>
<SENT sid="13" pm="."><plain>Prophylactic <z:chebi fb="2" ids="17650">hydrocortisone</z:chebi> administration appears to have a therapeutic value in inducing <z:hpo ids='HP_0011105'>hypervolemia</z:hpo> efficiently after SAH </plain></SENT>
</text></document>